Pulmonary Arterial Hypertension Related to Connective Tissue Disease. A Review.

Rheumatic Disease Clinics of North America

Volumn 40, Issue 1, 2014, Pages 103-124

  Ahmed, Saman ^a   Palevsky, Harold I ^a  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

Associated pulmonary arterial hypertension; Connective tissue disease related PAH; PAH and scleroderma; PAH and systemic lupus erythematosus; Pulmonary arterial hypertension; Transthoracic echocardiogram in pulmonary arterial hypertension

Indexed keywords

ADAMPAS; AMBRISENTAN; ANGIOPOIETIN 1; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; DIGOXIN; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; IMATINIB; IMMUNOSUPPRESSIVE AGENT; LA ANTIBODY; MACITENTAN; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; RHEUMATOID FACTOR; RIBONUCLEOPROTEIN ANTIBODY; RIOCIGUAT; RO ANTIBODY; SELEXIPAG; SILDENAFIL; TADALAFIL; TRANSFORMING GROWTH FACTOR BETA; TREPROSTINIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE RESPIRATORY FAILURE; CLINICAL FEATURE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; CONTINUOUS INFUSION; DERMATOMYOSITIS; DIARRHEA; DIFFUSE SCLERODERMA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DIZZINESS; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; EARLY DIAGNOSIS; ERYTHROCYTE SEDIMENTATION RATE; EXERCISE TOLERANCE; FAINTNESS; HEADACHE; HEART CATHETERIZATION; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; HOT FLUSH; HUMAN; HYPERTRANSAMINASEMIA; INFUSION SITE PAIN; JAW PAIN; LABORATORY TEST; LIMITED SCLERODERMA; LOW DRUG DOSE; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; MIXED CONNECTIVE TISSUE DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; NOSE OBSTRUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PATHOGENESIS; PERIPHERAL EDEMA; POLYMYOSITIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SCREENING; SJOEGREN SYNDROME; SUBDURAL HEMATOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSTHORACIC ECHOCARDIOGRAPHY; UNSPECIFIED SIDE EFFECT;

ASSOCIATED PULMONARY ARTERIAL HYPERTENSION; CONNECTIVE TISSUE DISEASE RELATED PAH; PAH AND SCLERODERMA; PAH AND SYSTEMIC LUPUS ERYTHEMATOSUS; PULMONARY ARTERIAL HYPERTENSION; TRANSTHORACIC ECHOCARDIOGRAM IN PULMONARY ARTERIAL HYPERTENSION;

ARTHRITIS, RHEUMATOID; CONNECTIVE TISSUE DISEASES; DERMATOMYOSITIS; HUMANS; HYPERTENSION, PULMONARY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIXED CONNECTIVE TISSUE DISEASE; SJOGREN-LARSSON SYNDROME;

EID: 84888147376     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2013.10.001     Document Type: Review

References (131)

1. Vogel-Claussen J., Skrok J., Shehata M.L., et al. Right and left ventricular myocardial perfusion reserves correlate with right ventricular function and pulmonary hemodynamics in patients with pulmonary arterial hypertension. Radiology 2011, 258(1):119-127.
2. Hassoun P.M. Pulmonary arterial hypertension complicating connective tissue diseases. Semin Respir Crit Care Med 2009, 30(4):429-439.
3. Opitz C.F., Blindt R., Blumberg F., et al. Pulmonary hypertension: hemodynamic evaluation: hemodynamic evaluation-recommendations of the Cologne Consensus Conference 2010. Dtsch Med Wochenschr 2010, 135(Suppl 3):S78-S86.
4. Montani D., Chaouat A. Diagnosis and classification of pulmonary hypertension. Presse Med 2010, 39(Suppl 1). 1S3-15.
5. Badesch D.B., Raskob G.E., Elliott C.G., et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010, 137(2):376-387.
6. Hoeper M.M. Definition, classification, and epidemiology of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009, 30(4):369-375.
7. Kovacs G., Olschewski H. Pulmonary arterial pressure during rest and exercise (from Geneva, 1961 to Dana Point, 2008). Annals of Respiratory Medicine 2010, 1(2).
8. Simonneau G. Anew clinical classification of pulmonary hypertension. Bull Acad Natl Med 2009, 193(8):1897-1909.
9. Rich S. Primary pulmonary hypertension: executive summary from the World Symposium (Evian, France - 1998). 1998. Available at: Accessed August 1, 2013. http://www.who.int/ncd/cvd/pph.htm.
10. Fishman A.P. Clinical classification of pulmonary hypertension. Clin Chest Med 2001, 22(3):385-391. vii.
11. Humbert M., Nunes H., Sitbon O., et al. Risk factors for pulmonary arterial hypertension. Clin Chest Med 2001, 22(3):459-475.
12. Dadfarmay S., Berkowitz R., Kim B., et al. Differentiating pulmonary arterial and pulmonary venous hypertension and the implications for therapy. Congest Heart Fail 2010, 16(6):287-291.
13. Fauzi A. Primary pulmonary hypertension. Med J Malaysia 2000, 55(4):529-537. [quiz: 538].
14. Proceedings of the 3rd World Symposium on Pulmonary Arterial Hypertension (Venice, Italy) June 23-25, 2003. JAm Coll Cardiol 2004, 43:S1-S90.
15. Hsu V.M., Moreyra A.E., Wilson A.C., et al. Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. JRheumatol 2008, 35(3):458-465.
16. Simonneau G., Robbins I.M., Beghetti M., et al. Updated clinical classification of pulmonary hypertension. JAm Coll Cardiol 2009, 54(Suppl 1):S43-S54.
17. Gurubhagavatula I., Palevsky H.I. Pulmonary hypertension in systemic autoimmune disease. Rheum Dis Clin North Am 1997, 23(2):365-394.
18. Chemla D., Castelain V., Herve P., et al. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J 2002, 20(5):1314-1331.
19. Humbert M., Morrell N.W., Archer S.L., et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. JAm Coll Cardiol 2004, 43(12 Suppl S):13S-24S.
20. Lim K.A., Kim K.C., Cho M.S., et al. Gene expression of endothelin-1 and endothelin receptor a on monocrotaline-induced pulmonary hypertension in rats after bosentan treatment. Korean Circ J 2010, 40(9):459-464.
21. Chen C.N., Watson G., Zhao L. Cyclic guanosine monophosphate signalling pathway in pulmonary arterial hypertension. Vascul Pharmacol 2012, 58(3):211-218.
22. Mahowald M.L., Weir E.K., Ridley D.J., et al. Pulmonary hypertension in systemic lupus erythematosus: effect of vasodilators on pulmonary hemodynamics. JRheumatol 1985, 12(4):773-777.
23. Jonigk D., Golpon H., Bockmeyer C.L., et al. Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. Am J Pathol 2011, 179(1):167-179.
24. Austin E., Lahm T., West J., et al. Gender, sex hormones and pulmonary hypertension. Pulm Circ 2013, 3(2):294-314.
25. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987, 107(2):216-223.
26. Fagan K. Pulmonary arterial hypertension. Current diagnosis and treatment in pulmonary medicine 2003, McGraw-Hill, New York, Available at:, Accessed July 24, 2013. http://www.accessmedicine.com/content.aspx?aID=576600, M. Hanley, C. Welsh (Eds.).
27. Palevsky H.I. The early diagnosis of pulmonary arterial hypertension: can we do better?. Chest 2011, 140(1):4-6.
28. Zhang R.F., Zhou L., Ma G.F., et al. Diagnostic value of transthoracic Doppler echocardiography in pulmonary hypertension: a meta-analysis. Am J Hypertens 2010, 23(12):1261-1264.
29. Goto K., Arai M., Watanabe A., et al. Utility of echocardiography versus BNP level for the prediction of pulmonary arterial pressure in patients with pulmonary arterial hypertension. Int Heart J 2010, 51(5):343-347.
30. Badesch D.B., Champion H.C., Sanchez M.A., et al. Diagnosis and assessment of pulmonary arterial hypertension. JAm Coll Cardiol 2009, 54(Suppl 1):S55-S66.
31. Celebi Sozener Z., Karabiyikoglu G., Duzgun N. Evaluation of the functional parameters in scleroderma cases with pulmonary involvement. Tuberk Toraks 2010, 58(3):235-241.
32. Sanchez O., Marie E., Lerolle U., et al. Pulmonary arterial hypertension in women. Rev Mal Respir 2008, 25(4):451-460. [in French].
33. Mathai S.C., Sibley C.T., Forfia P.R., et al. Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension. JRheumatol 2011, 38(11):2410-2418.
34. Saito Y., Nakamura K., Miyaji K., et al. Acute vasoreactivity testing with nicardipine in patients with pulmonary arterial hypertension. JPharmacol Sci 2012, 120(3):206-212.
35. Shimony A., Fox B.D., Langleben D., et al. Incidence and significance of pericardial effusion in patients with pulmonary arterial hypertension. Can J Cardiol 2013, 29(6):678-682.
36. Eysmann S.B., Palevsky H.I., Reichek N., et al. Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation 1989, 80(2):353-360.
37. Burger C., Zeigler T. What can be learned in 6 minutes? 6-minute walk test: primer and role in pulmonary arterial hypertension. Adv Pulm Hypertens 2010, 9(2):107-111.
38. Impens A.J., Wangkaew S., Seibold J.R. The 6-minute walk test in scleroderma-how measuring everything measures nothing. Rheumatology (Oxford) 2008, 47(Suppl 5):v68-v69.
39. Wasserman K., Hansen J., Sue D., et al. Principles of exercise testing and interpretation 2005, Lea and Febiger, Philadelphia. 4th edition.
40. Heresi G.A., Tang W.H., Aytekin M., et al. Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension. Eur Respir J 2012, 39(4):939-944.
41. Rhodes C.J., Wharton J., Howard L.S., et al. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart 2011, 97(13):1054-1060.
42. Cracowski J.L., Leuchte H.H. The potential of biomarkers in pulmonary arterial hypertension. Am J Cardiol 2012, 110(Suppl 6):32S-38S.
43. Hesselstrand R., Scheja A., Wuttge D.M., et al. Enlarged right-sided dimensions and fibrosis of the right ventricular insertion point on cardiovascular magnetic resonance imaging is seen early in patients with pulmonary arterial hypertension associated with connective tissue disease. Scand J Rheumatol 2011, 40(2):133-138.
44. Haage P., Piroth W., Krombach G., et al. Pulmonary embolism: comparison of angiography with spiral computed tomography, magnetic resonance angiography, and real-time magnetic resonance imaging. Am J Respir Crit Care Med 2003, 167(5):729-734.
45. Nicod P., Moser K.M. Primary pulmonary hypertension. The risk and benefit of lung biopsy. Circulation 1989, 80(5):1486-1488.
46. Prabu A., Patel K., Yee C.S., et al. Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. Rheumatology (Oxford) 2009, 48(12):1506-1511.
47. Vachiery J.L., Coghlan G. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2009, 18(113):162-169.
48. Rajaram S., Swift A.J., Capener D., et al. Comparison of the diagnostic utility of cardiac magnetic resonance imaging, computed tomography, and echocardiography in assessment of suspected pulmonary arterial hypertension in patients with connective tissue disease. JRheumatol 2012, 39(6):1265-1274.
49. Morrell N.W., Adnot S., Archer S.L., et al. Cellular and molecular basis of pulmonary arterial hypertension. JAm Coll Cardiol 2009, 54(Suppl 1):S20-S31.
50. Proudman S.M., Stevens W.M., Sahhar J., et al. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J 2007, 37(7):485-494.
51. Chung L., Liu J., Parsons L., et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010, 138(6):1383-1394.
52. Callejas-Rubio J.L., Moreno-Escobar E., de la Fuente P.M., et al. Prevalence of exercise pulmonary arterial hypertension in scleroderma. JRheumatol 2008, 35(9):1812-1816.
53. Bijl M., Bootsma H., Kallenberg C.G. Pulmonary arterial hypertension in systemic lupus erythematosus: should we bother?. Rheumatology (Oxford) 2009, 48(12):1471-1472.
54. Koh E.T., Lee P., Gladman D.D., et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996, 35(10):989-993.
55. Campo A., Mathai S.C., Le Pavec J., et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010, 182(2):252-260.
56. Hassoun P.M. Therapies for scleroderma-related pulmonary arterial hypertension. Expert Rev Respir Med 2009, 3(2):187-196.
57. van Laar J.M., Stolk J., Tyndall A. Scleroderma lung: pathogenesis, evaluation and current therapy. Drugs 2007, 67(7):985-996.
58. Carmier D., Marchand-Adam S., Diot P., et al. Respiratory involvement in systemic lupus erythematosus. Rev Mal Respir 2008, 25(10):1289-1303.
59. Guillevin L. Vasculopathy and pulmonary arterial hypertension. Rheumatology (Oxford) 2009, 48(Suppl 3):iii54-iii57.
60. Launay D., Hachulla E., Hatron P.Y., et al. Pulmonary arterial hypertension: a rare complication of primary Sjogren syndrome: report of 9 new cases and review of the literature. Medicine 2007, 86(5):299-315.
61. Tillie-Leblond I., Colin G., Lelong J., et al. Pulmonary involvement in polymyositis and dermatomyositis. Rev Mal Respir 2006, 23(6):671-680. [in French].
62. Nagasaka J., Harigai M., Tateis M., et al. Efficacy of combination treatment with cyclosporin A and corticosteroids for acute interstitial pneumonitis associated with dermatomyositis. Mod Rheumatol 2003, 13:231-238.
63. Benedict N., Seybert A., Mathier M.A. Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin Ther 2007, 29(10):2134-2153.
64. Oudiz R.J., Schilz R.J., Barst R.J., et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004, 126(2):420-427.
65. Frumkin L.R. The pharmacological treatment of pulmonary arterial hypertension. Pharmacol Rev 2012, 64(3):583-620.
66. Mathai S.C., Hassoun P.M. Therapy for pulmonary arterial hypertension associated with systemic sclerosis. Curr Opin Rheumatol 2009, 21(6):642-648.
67. Galie N., Seeger W., Naeije R., et al. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. JAm Coll Cardiol 2004, 43(12 Suppl S):81S-88S.
68. Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. NEngl J Med 2004, 351(14):1425-1436.
69. Porhownik N., Al Sharif H., Bshouty Z. Addition of sildenafil in patients with pulmonary arterial hypertension and inadequate response to bosentan monotherapy. Can Respir J 2008, 15(8):427-430.
70. McLaughlin V., Humbert M., Coghlan G., et al. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford) 2009, 48(Suppl 3):iii25-iii31.
71. Vachiery J.L. Prostacyclins in pulmonary arterial hypertension: the need for earlier therapy. Adv Ther 2011, 28(4):251-269.
72. Nadler S.T., Edelman J.D. Inhaled treprostinil and pulmonary arterial hypertension. Vasc Health Risk Manag 2010, 6:1115-1124.
73. Schachna L., Wigley F.M. Targeting mediators of vascular injury in scleroderma. Curr Opin Rheumatol 2002, 14(6):686-693.
74. Badesch D.B., McLaughlin V.V., Delcroix M., et al. Prostanoid therapy for pulmonary arterial hypertension. JAm Coll Cardiol 2004, 43(12 Suppl S):56S-61S.
75. Simonneau G., Torbicki A., Hoeper M.M., et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012, 40(4):874-880.
76. Badesch D.B., Abman S.H., Ahearn G.S., et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004, 126(Suppl 1):35S-62S.
77. Barst R.J., Rubin L.J., Long W.A., The Primary Pulmonary Hypertension Study Group, et al. Acomparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. NEngl J Med 1996, 334(5):296-302.
78. Barst R.J., Rubin L.J., McGoon M.D., et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994, 121(6):409-415.
79. Shapiro S.M., Oudiz R.J., Cao T., et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. JAm Coll Cardiol 1997, 30(2):343-349.
80. McLaughlin V.V., Genthner D.E., Panella M.M., et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. NEngl J Med 1998, 338(5):273-277.
81. McLaughlin V.V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002, 106(12):1477-1482.
82. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. JAm Coll Cardiol 2002, 40(4):780-788.
83. Humbert M., Sanchez O., Fartoukh M., et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 1999, 13(6):1351-1356.
84. Badesch D.B., McGoon M.D., Barst R.J., et al. Long-term survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. JRheumatol 2009, 36(10):2244-2249.
85. Gaine S.P., Rubin L.J. Medical and surgical treatment options for pulmonary hypertension. Am J Med Sci 1998, 315(3):179-184.
86. Rubin L.J. Primary pulmonary hypertension. NEngl J Med 1997, 336(2):111-117.
87. Yanagisawa M., Kurihara H., Kimura S., et al. Anovel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332(6163):411-415.
88. Dupuis J., Stewart D.J., Cernacek P., et al. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996, 94(7):1578-1584.
89. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001, 358(9288):1119-1123.
90. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. NEngl J Med 2002, 346(12):896-903.
91. Galie N., Rubin L., Hoeper M., et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008, 371(9630):2093-2100.
92. Galie N., Olschewski H., Oudiz R.J., et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008, 117(23):3010-3019.
93. Bolli M.H., Boss C., Binkert C., et al. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-p ropylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. JMed Chem 2012, 55(17):7849-7861.
94. Mikhail G.W., Prasad S.K., Li W., et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J 2004, 25(5):431-436.
95. Michelakis E., Tymchak W., Lien D., et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002, 105(20):2398-2403.
96. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. NEngl J Med 2005, 353(20):2148-2157.
97. Zhao L., Mason N.A., Morrell N.W., et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001, 104(4):424-428.
98. Sastry B.K., Narasimhan C., Reddy N.K., et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. JAm Coll Cardiol 2004, 43(7):1149-1153.
99. Wilkins M.R., Paul G.A., Strange J.W., et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am J Respir Crit Care Med 2005, 171(11):1292-1297.
100. Badesch D.B., Hill N.S., Burgess G., et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. JRheumatol 2007, 34(12):2417-2422.
101. Levin Y.D., White R.J. Novel therapeutic approaches in pulmonary arterial hypertension: focus on tadalafil. Drugs Today (Barc) 2011, 47(2):145-156.
102. Falk J.A., Philip K.J., Schwarz E.R. The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. Vasc Health Risk Manag 2010, 6:273-280.
103. Oudiz R.J., Brundage B.H., Galie N., et al. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. JAm Coll Cardiol 2012, 60(8):768-774.
104. Grimminger F., Schermuly R.T., Ghofrani H.A. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov 2010, 9(12):956-970.
105. Sakao S., Tatsumi K. Vascular remodeling in pulmonary arterial hypertension: multiple cancer-like pathways and possible treatment modalities. Int J Cardiol 2011, 147(1):4-12.
106. Ghofrani H.A., Morrell N.W., Hoeper M.M., et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010, 182(9):1171-1177.
107. Song K.W., Rifkind J., Al-Beirouti B., et al. Subdural hematomas during CML therapy with imatinib mesylate. Leuk Lymphoma 2004, 45(8):1633-1636.
108. Patel S.B., Gojo I., Tidwell M.L., et al. Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. Leuk Lymphoma 2011, 52(7):1211-1214.
109. Michelakis E.D. Soluble guanylate cyclase stimulators as a potential therapy for PAH: enthusiasm, pragmatism and concern. Eur Respir J 2009, 33(4):717-721.
110. Schermuly R.T., Janssen W., Weissmann N., et al. Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig Drugs 2011, 20(4):567-576.
111. Ghofrani H., Galie N., Grimminger F., et al. Riociguat for the treatment of pulmonary arterial hypertension. NEngl J Med 2013, 369:330-340.
112. Mittendorf J., Weigand S., Alonso-Alija C., et al. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 2009, 4(5):853-865.
113. Gentile M.A. Inhaled medical gases: more to breathe than oxygen. Respir Care 2011, 56(9):1341-1357. [discussion: 1357-49].
114. Hoeper M.M., Markevych I., Spiekerkoetter E., et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005, 26(5):858-863.
115. Kemp K., Savale L., O'Callaghan D.S., et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. JHeart Lung Transplant 2012, 31(2):150-158.
116. Simonneau G., Rubin L.J., Galie N., et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008, 149(8):521-530.
117. Fox B.D., Shimony A., Langleben D. Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. Am J Cardiol 2011, 108(8):1177-1182.
118. Humbert M., Barst R.J., Robbins I.M., et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004, 24(3):353-359.
119. McLaughlin V.V., Benza R.L., Rubin L.J., et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. JAm Coll Cardiol 2010, 55(18):1915-1922.
120. Lordan J.L., Corris P.A. Pulmonary arterial hypertension and lung transplantation. Expert Rev Respir Med 2011, 5(3):441-454.
121. Long J., Russo M.J., Muller C., et al. Surgical treatment of pulmonary hypertension: lung transplantation. Pulm Circ 2011, 1(3):327-333.
122. Kamler M., Pizanis N., Aleksic I., et al. Pulmonary hypertension and lung transplantation. Herz 2005, 30(4):281-285. [in German].
123. Levine S.M., Anzueto A., Peters J.I., et al. Single lung transplantation in patients with systemic disease. Chest 1994, 105(3):837-841.
124. Pigula F.A., Griffith B.P., Zenati M.A., et al. Lung transplantation for respiratory failure resulting from systemic disease. Ann Thorac Surg 1997, 64(6):1630-1634.
125. Rosas V., Conte J.V., Yang S.C., et al. Lung transplantation and systemic sclerosis. Ann Transplant 2000, 5(3):38-43.
126. Denton C.P., Hachulla E. Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening. Eur Respir Rev 2011, 20(122):270-276.
127. Condliffe R., Kiely D.G., Peacock A.J., et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009, 179(2):151-157.
128. Benza R.L., Miller D.P., Barst R.J., et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012, 142(2):448-456.
129. Kovacs G., Maier R., Aberer E., et al. Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. Arthritis Rheum 2012, 64(4):1257-1262.
130. Olschewski H. Pulmonary hypertension: the future has begun. Med Klin (Munich) 2006, 101(4):328-333.
131. Agarwal R., Gomberg-Maitland M. Current therapeutics and practical management strategies for pulmonary arterial hypertension. Am Heart J 2011, 162(2):201-213.